The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 901–1,000 of 1,000
Targeting protein kinase C in mantle cell lymphoma
Rauert‐Wunderlich, H., Rudelius, M., Ott, G., & Rosenwald, A. (2016) · British Journal of Haematology · doi:10.1111/bjh.13973 · Cited by 10
Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma
Rosenthal, A. C. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0383-0 · Cited by 10
Rational therapeutic choice for older patients with lymphoma
Bron, D., & Soubeyran, P. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000394 · Cited by 10
Shimono, J., Izumiyama, K., Ito, S., Tsutsmi, Y., Kondo, T., Kakinoki, Y., & Teshima, T. (2020) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.13216 · Cited by 10
Gauthier, J., & Maloney, D. G. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.06.010 · Cited by 10
Wang, K., Xu, Q., & Zhong, H. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.625498 · Cited by 10
Izutsu, K., Suzumiya, J., Takizawa, J., Fukase, K., Nakamura, M., Jinushi, M., & Nagai, H. (2021) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.20056 · Cited by 10
SOX11 Inhibitors Are Cytotoxic in Mantle Cell Lymphoma
Jatiani, S., Christie, S., Leshchenko, V. V., Jain, R., Kapoor, A., Bisignano, P., Lee, C., Kaniskan, H. Ü., Edwards, D., Meng, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-5039 · Cited by 11
Di, M., Cui, C., Kothari, S. K., Zeidan, A. M., Podoltsev, N. A., Neparidze, N., Shallis, R. M., Wang, R., Ma, X., & Huntington, S. F. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006934 · Cited by 10
Paillassa, J., Safa, F. M., & Troussard, X. (2022) · Therapeutic Advances in Hematology · doi:10.1177/20406207221090886 · Cited by 10
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Ameli, F., Shajareh, E., Mokhtari, M., & Kosari, F. (2022) · BMC Cancer · doi:10.1186/s12885-022-09803-x · Cited by 10
Venetoclax: A narrative drug review
Rajendra, A., & Sengar, M. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_179_22 · Cited by 11
Bruton's tyrosine kinase inhibitors
Ysebaert, L., & Michallet, A. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000114 · Cited by 10
Deploying Ibrutinib to Lung Cancer: Another Step in the Quest Towards Drug Repurposing
Haura, E. B., & Rix, U. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju250 · Cited by 10
Targeting childhood, adolescent and young adult non‐Hodgkin lymphoma: therapeutic horizons
Galardy, P. J., Bedekovics, T., & Hermiston, M. L. (2016) · British Journal of Haematology · doi:10.1111/bjh.14016 · Cited by 10
Emerging drugs for graft-versus-host disease
Kekre, N. K., & Antin, J. H. (2016) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2016.1170117 · Cited by 10
Mori, S., Patel, R. D., Ahmad, S., Varela, J. C., Smith, T., Altoos, R., Shen, Q., Goldstein, S. C., & Persky, D. O. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.11.007 · Cited by 10
Stephens, D. M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01414 · Cited by 10
Recall of ibrutinib and issues with therapeutic approval
Lipfert, C., Kim, M. S., Haslam, A., & Prasad, V. K. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2024-000418 · Cited by 10
Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies
Kala, J., Joseph, T., Pirovano, M., Fenoglio, R., & Cosmai, L. (2024) · Kidney360 · doi:10.34067/kid.0000000566 · Cited by 9
COOKIE-Pro: covalent inhibitor binding kinetics profiling on the proteome scale
Lin, H., Yang, B., Ding, L., Yang, Y., Holt, M. V., Jung, S. Y., Zhang, B., Wang, M. C., & Wang, J. (2025) · Nature Communications · doi:10.1038/s41467-025-63491-2 · Cited by 10
Self-citationMapping cellular targets of covalent cancer drugs in the entire mammalian body
Pang, Z., Leung, V. H., Wang, C. C., Attarpour, A., Rinaldi, A., Shen, H., Moya-Garzón, M. D., Sigua, L. H., Rammel, C., Selke, A., et al. (2025) · Cell · doi:10.1016/j.cell.2025.11.030 · Cited by 9
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Varma, G., Johnson, T. P., & Advani, R. H. (2016) · PubMed · Cited by 9
Self-citationCurrent treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla, E., Atilla, P. A., & Demirer, T. (2016) · International Journal of Hematology · doi:10.1007/s12185-016-2164-2 · Cited by 9
Matissek, S. J., Han, W., Karbalivand, M., Sayed, M., Reilly, B. M., Mallat, S., Ghazal, S. M., Munshi, M. N., Yang, G., Treon, S. P., et al. (2020) · Epigenomics · doi:10.2217/epi-2020-0189 · Cited by 9
Rip, J., de Bruijn, M. J. W., Neys, S. F. H., Singh, S. P., Willar, J., van Hulst, J. A. C., Hendriks, R. W., & Corneth, O. B. J. (2021) · European Journal of Immunology · doi:10.1002/eji.202048968 · Cited by 9
Di, M., Long, J. B., Kothari, S. K., Sethi, T. K., Zeidan, A. M., Podoltsev, N. A., Shallis, R. M., Wang, R., Ma, X., & Huntington, S. F. (2023) · Haematologica · doi:10.3324/haematol.2022.282252 · Cited by 9
Jha, K. T., Shome, A., Chahat, Chawla, V., & Chawla, P. A. (2023) · Process Biochemistry · doi:10.1016/j.procbio.2023.07.018 · Cited by 9
Unraveling MCL biology to understand resistance and identify vulnerabilities
Sarkozy, C., Tessoulin, B., & Chiron, D. (2024) · Blood · doi:10.1182/blood.2023022351 · Cited by 9
Chaganti, S., Maycock, S., McIlroy, G., Jackson, A. E., Bishop, R., Johnson, S., Kanfer, E., Kassam, S., Cwynarski, K., Wrench, D., et al. (2024) · Blood · doi:10.1182/blood.2024023847 · Cited by 9
Covalent drug – An emerging framework for targeted drug development
Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V., & Chaudhari, S. Y. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101615 · Cited by 10
Liebers, N., Boumendil, A., Finel, H., Edelmann, D., Kobbe, G., Baermann, B., Serroukh, Y. I. M., Blaise, D., Beelen, D. W., Solano, C., et al. (2025) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0178 · Cited by 9
Treatment options for mantle cell lymphoma
Smolewski, P., Witkowska, M., & Robak, T. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1087507 · Cited by 9
Recent advances in mantle cell lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop
Gordon, L. I., Bernstein, S. H., Jares, P., Kahl, B. S., Witzig, T. E., & Dreyling, M. H. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.876634 · Cited by 9
Self-citationPost-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Epperla, N., Fenske, T. S., Lazarus, H. M., & Hamadani, M. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.184 · Cited by 9
The evolving role of targeted biological agents in the management of indolent B-cell lymphomas
Wang, T. P., Scott, J. H., & Barta, S. K. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717738740 · Cited by 9
Acalabrutinib in mantle cell lymphoma
Kapoor, P., & Ansell, S. M. (2017) · The Lancet · doi:10.1016/s0140-6736(17)33256-7 · Cited by 9
Use of acalabrutinib in patients with mantle cell lymphoma
Awan, F. T., & Jurczak, W. J. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1473030 · Cited by 9
Self-citationNovel agents for mantle cell lymphoma: molecular rational and clinical data
Sarkozy, C., & Ribrag, V. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1760245 · Cited by 10
Tessoulin, B., Bouabdallah, K., Burroni, B., Lamy, T., Gressin, R., Cartron, G., Thiéblemont, C., Sarkozy, C., Haïoun, C., Casasnovas, O., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04159-3 · Cited by 9
Ismail, A. I. (2021) · Journal of Spectroscopy · doi:10.1155/2021/9968797 · Cited by 9
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia
Lasica, M., & Tam, C. S. L. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.03.006 · Cited by 9
Das, D., Xie, L., Wang, J., Qiao, D., & Hong, J. (2022) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162022010046 · Cited by 9
Elbezanti, W. O., Al‐Odat, O. S., Chitren, R. J., Singh, J. K., Srivastava, S. K., Gowda, K., Amin, S., Robertson, G. P., Nemmara, V. V., Jonnalagadda, S. C., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.894535 · Cited by 9
Song, Y., Wu, S., Shen, Z., Zhao, D., Chan, T. S. Y., Huang, H., Qiu, L., Li, J., Tan, T., Zhu, J., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00448-5 · Cited by 9
Ibrutinib—a new standard treatment for relapsed mantle cell lymphoma?
Martin, P. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01040-5 · Cited by 9
Self-citationDeciphering Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Lenz, G. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.0102 · Cited by 9
Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells
Badieyan, Z. S., & Hoseini, S. S. (2018) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-018-0507-9 · Cited by 9
Diamond, B. T., & Kumar, A. A. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.03.002 · Cited by 9
Selberg, L., Stadtherr, P., Dietrich, S., Tran, T. H., Luft, T., Hegenbart, U., Bondong, A., Meißner, J., Liebers, N., Schmitt, M. W., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0976-4 · Cited by 9
Fan, Q., Ma, J., Zhang, B., Li, Q., Liu, F., & Zhao, B. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04151-8 · Cited by 9
Ibrutinib: A narrative drug review
Mehra, N., Bagal, B. P., Munot, P., & Mirgh, S. P. (2020) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_234_20 · Cited by 9
Cellular Therapies for Mantle Cell Lymphoma
Yassine, F., Sandoval-Sus, J. D., Ayala, E., Chávez, J. C., Hamadani, M., & Kharfan‐Dabaja, M. A. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.01.026 · Cited by 9
Yuan, J., Zhang, Q. H., Wu, S., Yan, S., Zhao, R., Sun, Y., Tian, X., & Zhou, K. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.08.010 · Cited by 9
Walking, Writing and Performance: Autobiographical Texts
Heddon, D. E., Lavery, C., & Smith, P. J. (2009) · Cited by 9
Darragh, A. C., Hanna, A. M., Lipner, J., King, A. J., Servant, N. B., & Jahic, M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00540 · Cited by 8
Dreger, P., Ahmed, S., Bazarbachi, A. A., Dietrich, S., Fenske, T. S., Ghosh, N., Hermine, O., & Hamadani, M. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02599-x · Cited by 8
A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma
Qualls, D. A., Lam, H. Y., Whiting, K. A., Kumar, A. A., Matasar, M. J., Owens, C. N., Nichols, C., Espeleta, J. A., Qiu, A. Q., Subzwari, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006555 · Cited by 8
How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients with CLL?
Rhodes, J. M., Barrientos, J. C., & Rai, K. R. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01322-z · Cited by 8
Self-citationInhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells
Gélébart, P., Gjerstad, M. E., Benjaminsen, S., Han, J., Karlsen, I. T., Safont, M. M., Leitch, C., Fandalyuk, Z., Popa, M. L., Helgeland, L., et al. (2023) · Blood · doi:10.1182/blood.2022015581 · Cited by 8
The Role of mTOR in B Cell Lymphoid Malignancies: Biologic and Therapeutic Aspects
Karatrasoglou, E. A., Dimou, M., Piperidou, A., Lakiotaki, E., Korkolopoulou, P. A., & Vassilakopoulos, T. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814110 · Cited by 8
miR‐17‐92 cluster‐BTG2 axis regulates B‐cell receptor signaling in mantle cell lymphoma
Kawaji‐Kanayama, Y., Tsukamoto, T., Nakano, M., Tokuda, Y., Nagata, H., Mizuhara, K., Katsuragawa‐Taminishi, Y., Isa, R., Fujino, T., Matsumura‐Kimoto, Y., et al. (2023) · Cancer Science · doi:10.1111/cas.16027 · Cited by 8
Nylund, P., Nikkarinen, A., Ek, S., & Glimelius, I. C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1373269 · Cited by 8
Advancements in B‐Cell Non‐Hodgkin’s Lymphoma: From Signaling Pathways to Targeted Therapies
Alfaifi, A., Bahashwan, S., Alsaadi, M., Ageel, A. H., Ahmed, H. H., Fatima, K., Malhan, H. M., Qadri, I., & Almehdar, H. A. (2024) · Advances in Hematology · doi:10.1155/2024/5948170 · Cited by 8
Pan, Y., Zhao, Y., Ren, H., Wang, X., Liu, C., Du, B., Nanthakumar, K., & Yang, P. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1513913 · Cited by 8
The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma
Munakata, W., & Tobinai, K. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1233174 · Cited by 8
Sun, S., Cheng, D., Kong, S., Li, X., Li, T., Yu, Q.-L., & Wang, L. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4703 · Cited by 8
Novel Treatments for Mantle Cell Lymphoma: From Targeted Therapies to CAR T Cells
Wallace, D. S., & Reagan, P. M. (2021) · Drugs · doi:10.1007/s40265-021-01497-y · Cited by 8
Feng, M. H., Wang, J., Sun, M., Li, G., Li, B., & Zhang, H. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01980-2 · Cited by 8
Issahaku, A. R., & Soliman, M. E. S. (2022) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201023666220617151552 · Cited by 8
Casulo, C., Santoro, A., Cartron, G., Ando, K., Munoz, J. L., Gouill, S. L., Izutsu, K., Rule, S. A., Lugtenburg, P. J., Ruan, J., et al. (2022) · Cancer Reports · doi:10.1002/cnr2.1662 · Cited by 8
Self-citationKinase inhibitors for cancer alter metabolism, blood glucose, and insulin
Duggan, B. M., Marko, D. M., Muzaffar, R., Chan, D. Y., & Schertzer, J. D. (2022) · Journal of Endocrinology · doi:10.1530/joe-22-0212 · Cited by 8
Vaccinations in hematological patients in the era of target therapies: Lesson learnt from SARS-CoV-2
Fattizzo, B., Rampi, N., & Barcellini, W. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101077 · Cited by 8
Muto, S., Matsubara, T., Inoue, T., Kitamura, H., Yamamoto, K., Ishii, T., Yazawa, M., Yamamoto, R., Okada, N., Mori, K., et al. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02372-4 · Cited by 8
Recent advances in genomics and therapeutics in mantle cell lymphoma
Lu, T., Zhang, J., McCracken, J., & Young, K. H. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102651 · Cited by 8
Ibrutinib for Mantle Cell Lymphoma
Tucker, D. L., & Rule, S. A. (2016) · Future Oncology · doi:10.2217/fon.15.342 · Cited by 8
Self-citationNew biological therapies in Sjögren's syndrome
Nocturne, G., Cornec, D., Séror, R., & Mariette, X. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.02.009 · Cited by 8
Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy
Ruan, J., & Martin, P. (2016) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-016-0324-3 · Cited by 8
Self-citationCombining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines
Restelli, V., Lupi, M., Vagni, M., Chilà, R., Bertoni, F., Damia, G. L. M., & Carrassa, L. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0553-6 · Cited by 8
Kambhampati, S., Fakhri, B., Ai, W. Z., Kaplan, L. D., Tuscano, J. M., Wieduwilt, M. J., Sudhindra, A., Cavallone, E., Reiner, J., Aoun, C., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.020 · Cited by 8
Louedec, F. L., Gallais, F., Thomas, F., White‐Koning, M., Allal, B., Protin, C. A., Ysebaert, L., Chatelut, É., & Puisset, F. (2021) · Pharmaceuticals · doi:10.3390/ph14020162 · Cited by 8
Zhang, D., Xu, G., Zhao, J., Wang, Y., Wu, X., He, X., Li, W., Zhang, S., Yang, S., Ma, C., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113724 · Cited by 8
Targeting cell adhesion and homing as strategy to cure Waldenström's macroglobulinemia
Pals, S. T., Kersten, M. J., & Spaargaren, M. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.08.019 · Cited by 8
Bleeding and Thrombosis in Hematologic Neoplasia
Shatzel, J. J., Scherber, R. M., & DeLoughery, T. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-64263-5_59 · Cited by 8
CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma
Xavier, S., Nguyen, V. T., Khairnar, V., Phan, A. T., Yang, L., Nelson, M. S., Shukla, R. P., Wang, J., Li, A., Geng, H., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60208-3 · Cited by 7
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options?
Caserta, S., Martino, E. A., Vigna, E., Bruzzese, A., Amodio, N., Lucia, E., Olivito, V., Labanca, C., Mendicino, F., Morabito, F., et al. (2025) · European Journal Of Haematology · doi:10.1111/ejh.70036 · Cited by 7
Mantle cell lymphoma — State of the art — how to treat mantle cell lymphoma in Poland in 2025?
Romejko‐Jarosińska, J., & Pula, A. E. (2025) · Acta Haematologica Polonica · doi:10.5603/ahp.108364 · Cited by 7
Nephrotoxicity associated with anticancer agents: perspective on onconephrology from nephrologists
Matsubara, T., Yokoi, H., Yamada, H., & Yanagita, M. (2023) · International Journal of Clinical Oncology · doi:10.1007/s10147-023-02307-z · Cited by 7
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond
Gribbin, C. K., Chen, J., Martin, P., & Ruan, J. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2264430 · Cited by 7
Self-citationStella, F., Chiappella, A., Magni, M., Bonifazi, F., Philippis, C. D., Musso, M., Cutini, I., Ljevar, S., Barbui, A. M., Farina, M., et al. (2024) · British Journal of Haematology · doi:10.1111/bjh.19961 · Cited by 7
Bruton’s Tyrosine Kinase: A Double-Edged Sword in Cancer and Aging
Qusairy, Z., & Rada, M. (2025) · Kinases and Phosphatases · doi:10.3390/kinasesphosphatases3020010 · Cited by 7
Heß, G., Coiffier, B., Crump, M., Gisselbrecht, C., Offner, F. C., Romaguera, J. E., Kang, L., & Moran, P. J. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-015-0006-1 · Cited by 7
Self-citationNastoupil, L. J., Shenoy, P. J., Ambinder, A. J., Koff, J. L., Nooka, A. K., Waller, E. K., Langston, A. A., Seward, M., Kaufman, J. L., Bernal‐Mizrachi, L., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.921296 · Cited by 7
Cai, Q., Chen, Y., Zou, D., Zhang, L., Badillo, M., Zhou, S., Lopez, E., Jiang, W., Huang, H., Lin, T., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2255 · Cited by 7
Self-citationHanf, M., Chiron, D., de Visme, S., Touzeau, C., Maisonneuve, H., Jardel, H., Pellat‐Deceunynck, C., Amiot, M., & Gouill, S. L. (2016) · BMC Cancer · doi:10.1186/s12885-016-2844-6 · Cited by 7
Novel agents in mantle cell lymphoma
Tucker, D. L., & Rule, S. A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1328280 · Cited by 7
Self-citationRule, S. A., & Chen, R. W. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1506327 · Cited by 7
Self-citationAcalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma
Badillo, M., Nava, D., Rosa, M., Chen, W., Guerrero, M. D. C., & Wang, M. L. (2020) · Clinical journal of oncology nursing · doi:10.1188/20.cjon.392-398 · Cited by 7
Self-citationTariq, B., Ou, Y. C., Stern, J. C., Mundra, V., Doo, N. W., Walker, P., Lewis, K. L., Lin, C., Novotny, W. F., Sahasranaman, S., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2150820 · Cited by 7
SHP1 loss augments DLBCL cellular response to ibrutinib: a candidate predictive biomarker
Wu, W., Lu, P., Patel, P., Ma, J., Cai, K. Q., Mallikarjuna, V. S., Poureghbali, S., Nakhoda, S., Nejati, R., & Wang, Y. L. (2022) · Oncogene · doi:10.1038/s41388-022-02565-7 · Cited by 7
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
